Gastrin: An acid-releasing, proliferative and immunomodulatory peptide?

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 1, 2010, Pages 8-19

  Calatayud, Sara ^a   Álvarez, Ángeles ^a   Víctor, Víctor M ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

CCK 2 receptor antagonists; CCK 2 receptors; Gastrin; Iimmunomodulation; Inflammation

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 1 (2' METHYLPHENACYL) 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 2 OXO 1 PIVALOYLMETHYL 5 (2 PYRIDYL) 1H 1,4 BENZODIAZEPIN 3 YL] 3 [3 (METHYLAMINO)PHENYL]UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; ASPERLICIN; BENZOTRIPT; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CI 998; CR 1369; FAMOTIDINE; GASTRAZOLE; GASTRIN; GASTRIN RECEPTOR; GASTROINTESTINAL HORMONE; GV 150013X; ITRIGLUMIDE; JB 95008; OMEPRAZOLE; PREPROGASTRIN; PROGASTRIN; PROGLUMIDE; S 0509; SPIROGLUMIDE; UNCLASSIFIED DRUG; Z 360;

AMIDATION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; GASTRIN CELL; GASTRIN RELEASE; GENE EXPRESSION; HUMAN; HYPERGASTRINEMIA; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STOMACH ACID SECRETION; STOMACH CANCER; ZOLLINGER ELLISON SYNDROME;

ANIMALS; CELL PROLIFERATION; GASTRIC ACID; GASTRIN-SECRETING CELLS; GASTRINOMA; GASTRINS; GASTRITIS; HUMANS; IMMUNOMODULATION; PROTEIN PRECURSORS; RECEPTORS, CHOLECYSTOKININ; SIGNAL TRANSDUCTION;

EID: 77951123917     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710791112532     Document Type: Review

References (117)

1. Edkins, J.S. On the chemical mechanism of gastric secretion. Proc. R. Soc. Lond. B. Biol. Sci., 1905, 76, 376.
2. Edkins, J.S. The chemical mechanism of gastric secretion. J. Physiol., 1906, 34, 133-144
3. Gregory, H.; Hardy, P.M.; Jones, D.S.; Kenner, G.W.; Sheppard, R.C. The antral hormone gastrin. Structure of gastrin. Nature, 1964, 204, 931-933
4. Walsh, J.H. In: Gut Peptides: Biochemistry and Physiology; Walsh, Dockray, Eds.; Raven Press: New York, 1994; pp. 75-121.
5. Koh, T.J.; Chen, D. Gastrin as a growth factor in the gastrointestinal tract. Regul. Pept., 2000, 93, 37-44.
6. Rozengurt, E.; Walsh, J.H. Gastrin, CCK, signaling, and cancer. Annu. Rev. Physiol., 2001, 63, 49-76.
7. Crawley, J.N.; Corwin, R.L. Biological actions of cholecystokinin. Peptides, 1994, 15, 731-755
8. Dauge, V.; Lena, I. CCK in anxiety and cognitive processes. Neurosci. Biobehav. Rev., 1998, 22, 815-825
9. Dockray, G.; Dimaline, R.; Varro, A. Gastrin: old hormone, new functions. Pflugers Arch., 2005, 449, 344-355
10. Rehfeld, J.F. The art of measuring gastrin in plasma: a dwindling diagnostic discipline? Scand. J. Clin. Lab. Invest., 2008, 68, 353-361
11. Rengifo-Cam, W.; Singh, P. Role of progastrins and gastrins and their receptors in GI and pancreatic cancers: targets for treatment. Curr. Pharm. Des., 2004, 10, 2345-2358
12. Shulkes, A.; Baldwin, G. Biology and pathology of non-amidated gastrins. Scand. J. Clin. Lab. Invest. Suppl., 2001, 234, 123-128
13. Dufresne, M.; Seva, C.; Fourmy, D. Cholecystokinin and gastrin receptors. Physiol. Rev., 2006, 86, 805-847
14. Song, I.; Brown, D.R.; Wiltshire, R.N.; Gantz, I.; Trent, J.M.; Yamada, T. The human gastrin/cholecystokinin type B receptor gene: alternative splice donor site in exon 4 generates two variant mRNAs. Proc. Natl. Acad. Sci. USA, 1993, 90, 9085-9089
15. Miyake, A. A truncated isoform of human CCK-B/gastrin receptor generated by alternative usage of a novel exon. Biochem. Biophys. Res. Commun., 1995, 208, 230-237
16. Ding, W.Q.; Kuntz, S.M.; Miller, L.J. A misspliced form of the cholecystokinin-B/gastrin receptor in pancreatic carcinoma: role of reduced sellular U2AF35 and a suboptimal 3′-splicing site leading to retention of the fourth intron. Cancer Res., 2002, 62, 947-952
17. Hellmich, M.R.; Rui, X.L.; Hellmich, H.L.; Fleming, R.Y.; Evers, B.M.; Townsend, C.M., Jr. Human colorectal cancers express a constitutively active cholecystokinin-B/gastrin receptor that stimulates cell growth. J. Biol. Chem., 2000, 275, 32122-32128
18. Herranz, R. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med. Res. Rev., 2003, 23, 559-605.
19. Berna, M.J.; Tapia, J.A.; Sancho, V.; Jensen, R.T. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. Curr. Opin. Pharmacol., 2007, 7, 583-592
20. Kalindjian, S.B.; McDonald, I.M. Strategies for the design of non-peptide CCK2 receptor agonist and antagonist ligand. Curr. Top. Med. Chem., 2007, 7, 1195-1204
21. Rovati, A.L.; Casula, P.L.; Da Re, G. [Pharmacology and experimental toxicology of a new non-anticholinergic product with antisecretory and gastroprotective activity (CR 242, xylamide- Milid)]. Minerva Med., 1967, 58, 3656-3670
22. Revel, L.; Ferrari, F.; Makovec, F.; Rovati, L.C.; Impicciatore, M. Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative. Eur. J. Pharmacol., 1992, 216, 217-224
23. Makovec, F.; Revel, L.; Letari, O.; Mennuni, L.; Impicciatore, M. Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist. Eur. J. Pharmacol., 1999, 369, 81-90.
24. Chau, I.; Cunningham, D.; Russell, C.; Norman, A.R.; Kurzawinski, T.; Harper, P.; Harrison, P.; Middleton, G.; Daniels, F.; Hickish, T.; Prendeville, J.; Ross, P.J.; Theis, B.; Hull, R.; Walker, M.; Shankley, N.; Kalindjian, B.; Murray, G.; Gillbanks, A.; Black, J. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br. J. Cancer, 2006, 94, 1107-1115
25. Horwell, D.C.; Hughes, J.; Hunter, J.C.; Pritchard, M.C.; Richardson, R.S.; Roberts, E.; Woodruff, G.N. Rationally designed "dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. J. Med. Chem., 1991, 34, 404-414
26. Chang, R.S.; Lotti, V.J.; Monaghan, R.L.; Birnbaum, J.; Stapley, E.O.; Goetz, M.A.; Albers-Schonberg, G.; Patchett, A.A.; Liesch, J.M.; Hensens, O.D.; . A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science, 1985, 230, 177-179
27. Bock, M.G.; DiPardo, R.M.; Evans, B.E.; Rittle, K.E.; Whitter, W.L.; Veber, D.E.; Anderson, P.S.; Freidinger, R.M. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365, 260. J. Med. Chem., 1989, 32, 13-16
28. Nishida, A.; Takinami, Y.; Yuki, H.; Kobayashi, A.; Akuzawa, S.; Kamato, T.; Ito, H.; Yamano, M.; Nagakura, Y.; Miyata, K. YM022 [(R)-1-[2,3-dihydro-1- (2′-methylphenacyl)-2-oxo-5-phenyl- 1H- 1,4-benzodiazepin-3-yl]-3-(3- methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. J. Pharmacol. Exp. Ther., 1994, 270, 1256-1261
29. Semple, G.; Ryder, H.; Rooker, D.P.; Batt, A.R.; Kendrick, D.A.; Szelke, M.; Ohta, M.; Satoh, M.; Nishida, A.; Akuzawa, S.; Miyata, K. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo- 5-(2-pyridyl)-1H-1, 4-benzodiazepin-3-yl)-N'-(3-(methylamino) phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. J. Med. Chem., 1997, 40, 331-341
30. Reggiani, A.; Gerrard, P.A.; Mariaia, G.; Melotto, S.; Ratti, E.; Gaviraghi, G.; Trist, D.G. Anxiolytic activity of GV150013, a new potent and selective cholecystokinin-B (CCK-B) antagonist. Br. J. Pharmacol., 1995, 114, 92P.
31. Ursini, A.; Capelli, A.M.; Carr, R.A.; Cassara, P.; Corsi, M.; Curcuruto, O.; Curotto, G.; Dal Cin, M.; Davalli, S.; Donati, D.; Feriani, A.; Finch, H.; Finizia, G.; Gaviraghi, G.; Marien, M.; Pentassuglia, G.; Polinelli, S.; Ratti, E.; Reggiani, A.M.; Tarzia, G.; Tedesco, G.; Tranquillini, M.E.; Trist, D.G.; Van Amsterdam, F.T. Synthesis and SAR of new 5-phenyl-3-ureido-1,5- benzodiazepines as cholecystokinin-B receptor antagonists. J. Med. Chem., 2000, 43, 3596-3613
32. Yoneta, T.; Ukawa, H.; Fukuda, Y.; Eta, R.; Mera, Y.; Omata, T.; Kinomoto, T.; Kurimoto, T.; Ito, Z. Pharmacological Profiles of Z- 360, a Novel CCK-B/Gastrin (CCK2) Receptor Antagonist with Excellent Oral Potency. Gastroenterology, 2001, 120, A311.
33. Hagishita, S.; Murakami, Y.; Seno, K.; Kamata, S.; Haga, N.; Konoike, T.; Kanda, Y.; Kiyama, R.; Shiota, T.; Ishihara, Y.; Ishikawa, M.; Shimamura, M.; Abe, K.; Yoshimura, K. Synthesis and pharmacological properties of ureidomethylcarbamoylphenylketone derivatives. A new potent and subtype-selective nonpeptide CCK-B/gastrin receptor antagonist, S-0509. Bioorg. Med. Chem., 1997, 5, 1695-1714
34. Kulaksiz, H.; Arnold, R.; Goke, B.; Maronde, E.; Meyer, M.; Fahrenholz, F.; Forssmann, W.G.; Eissele, R. Expression and cell-specific localization of the cholecystokinin B/gastrin receptor in the human stomach. Cell Tissue Res., 2000, 299, 289-298
35. Schmitz, F.; Goke, M.N.; Otte, J.M.; Schrader, H.; Reimann, B.; Kruse, M.L.; Siegel, E.G.; Peters, J.; Herzig, K.H.; Folsch, U.R.; Schmidt, W.E. Cellular expression of CCK-A and CCK-B/gastrin receptors in human gastric mucosa. Regul. Pept., 2001, 102, 101-110
36. Walsh, J.H. In: Physiology of the gastrointestinal tract; Johnson, Alpers, Christensen, Jacobson, Walsh, Eds.; Raven Press: New York, 1994; pp. 1-128.
37. Koh, T.J.; Goldenring, J.R.; Ito, S.; Mashimo, H.; Kopin, A.S.; Varro, A.; Dockray, G.J.; Wang, T.C. Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice. Gastroenterology, 1997, 113, 1015-1025
38. Langhans, N.; Rindi, G.; Chiu, M.; Rehfeld, J.F.; Ardman, B.; Beinborn, M.; Kopin, A.S. Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptordeficient mice. Gastroenterology, 1997, 112, 280-286
39. Nagata, A.; Ito, M.; Iwata, N.; Kuno, J.; Takano, H.; Minowa, O.; Chihara, K.; Matsui, T.; Noda, T. G protein-coupled cholecystokinin- B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc. Natl. Acad. Sci. USA, 1996, 93, 11825-11830
40. Attoub, S.; Levasseur, S.; Buyse, M.; Goiot, H.; Laigneau, J.P.; Moizo, L.; Hervatin, F.; Marchand-Brustel, Y.; Lewin, J.M.; Bado, A. Physiological role of cholecystokinin B/gastrin receptor in leptin secretion. Endocrinology, 1999, 140, 4406-4410
41. Calam, J. Helicobacter pylori modulation of gastric acid. Yale J. Biol. Med., 1999, 72, 195-202.
42. Moss, S.F.; Legon, S.; Bishop, A.E.; Polak, J.M.; Calam, J. Effect of Helicobacter-pylori on gastric somatostatin in duodenal-ulcer disease. Lancet, 1992, 340, 930-932
43. Odum, L.; Petersen, H.D.; Andersen, I.B.; Hansen, B.F.; Rehfeld, J.F. Gastrin and somatostatin in Helicobacter-pylori infected antral mucosa. Gut, 1994, 35, 615-618
44. Weigert, N.; Schaffer, K.; Schusdziarra, V.; Classen, M.; Schepp, W. Gastrin secretion from primary cultures of rabbit antral G cells: Stimulation by inflammatory cytokines. Gastroenterology, 1996, 110, 147-154
45. Lehmann, F.S.; Golodner, E.H.; Wang, J.Y.; Chen, M.C.Y.; Avedian, D.; Calam, J.; Walsh, J.H.; Dubinett, S.; Soll, A.H. Mononuclear cells and cytokines stimulate gastrin release from canine antral cells in primary culture. Am. J. Physiol., 1996, 270, G783-G788.
46. Beales, I.; Blaser, M.J.; Srinivasan, S.; Calam, J.; PerezPerez, G.I.; Yamada, T.; Scheiman, J.; Post, L.; DelValle, J. Effect of Helicobacter pylori products and recombinant cytokines on gastrin release from cultured canine G cells. Gastroenterology, 1997, 113, 465-471
47. Wagner, S.; Haruma, K.; Gladziwa, U.; Soudah, B.; Gebel, M.; Bleck, J.; Schmidt, H.; Manns, M. Helicobacter-pylori infection and serum pepsinogen-A, pepsinogen-C, and gastrin in gastritis and peptic-ulcer - Significance of inflammation and effect of bacterial eradication. Am. J. Gastroenterol., 1994, 89, 1211-1218
48. Graham, D.Y.; Go, M.F.; Lew, G.M.; Genta, R.M.; Rehfeld, J.F. Helicobacter-pylori infection and exaggerated gastrin-release - Effects of inflammation and progastrin processing. Scand. J. Gastroenterol., 1993, 28, 690-694
49. Liu, Y.; Vosmaer, G.D.; Tytgat, G.N.; Xiao, S.D.; Ten Kate, F.J. Gastrin (G) cells and somatostatin (D) cells in patients with dyspeptic symptoms: Helicobacter pylori associated and non-associated gastritis. J. Clin. Pathol., 2005, 58, 927-931
50. Fukui, T.; Nishio, A.; Okazaki, K.; Uza, N.; Ueno, S.; Kido, M.; Inoue, S.; Kitamura, H.; Kiriya, K.; Ohashi, S.; Asada, M.; Tamaki, H.; Matsuura, M.; Kawasaki, K.; Suzuki, K.; Uchida, K.; Fukui, H.; Nakase, H.; Watanabe, N.; Chiba, T. Gastric mucosal hyperplasia via upregulation of gastrin induced by persistent activation of gastric innate immunity in major histocompatibility complex class II deficient mice. Gut, 2006, 55, 607-615
51. Vaananen, H.; Vauhkonen, M.; Helske, T.; Kaariainen, I.; Rasmussen, M.; Tunturi-Hihnala, H.; Koskenpato, J.; Sotka, M.; Turunen, M.; Sandstrom, R.; Ristikankare, M.; Jussila, A.; Sipponen, P. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin- 17 and pepsinogen I: a multicentre study. Eur. J. Gastroenterol. Hepatol., 2003, 15, 885-891
52. Germana, B.; di Mario, F.; Cavallaro, L.G.; Moussa, A.M.; Lecis, P.; Liatoupolou, S.; Comparato, G.; Carloni, C.; Bertiato, G.; Battiestel, M.; Papa, N.; Aragona, G.; Cavestro, G.M.; Iori, V.; Merli, R.; Bertolini, S.; Caruana, P.; Franze, A. Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care. Dig. Liver Dis., 2005, 37, 501-508
53. Graham, D.Y.; Nurgalieva, Z.Z.; El Zimaity, H.M.; Opekun, A.R.; Campos, A.; Guerrero, L.; Chavez, A.; Cardenas, V. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin. Gastroenterol. Hepatol., 2006, 4, 306-314
54. Leja, M.; Kupcinskas, L.; Funka, K.; Sudraba, A.; Jonaitis, L.; Ivanauskas, A.; Janciauskas, D.; Kiudelis, G.; Chiu, H.M.; Lin, J.T. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig. Dis. Sci, 2009, 54, 2377-2384
55. Reubi, J.C. Targeting CCK receptors in human cancers. Curr. Top. Med. Chem., 2007, 7, 1239-1242
56. Baldwin, G.S.; Shulkes, A. CCK receptors and cancer. Curr. Top. Med. Chem., 2007, 7, 1232-1238
57. Watson, S.; Durrant, L.; Morris, D. Gastrin: growth enhancing effects on human gastric and colonic tumour cells. Br. J. Cancer, 1989, 59, 554-558
58. Watson, S.A.; Durrant, L.G.; Morris, D.L. Growth-promoting action of gastrin on human colonic and gastric tumour cells cultured in vitro. Br. J. Surg., 1988, 75, 342-345
59. Ohkura, H.; Hanafusa, K.; Maruyama, K.; Kitaoka, H.; Watanabe, S.; Kameya, T. Gastrin-enhanced tumor growth of a xenotransplantable human gastric carcinoma in nude mice. Jpn. J. Clin. Oncol., 1980, 10, 255-263
60. Mathieu, V.; Mijatovic, T.; van Damme, M.; Kiss, R. Gastrin exerts pleiotropic effects on human melanoma cell biology. Neoplasia, 2005, 7, 930-943
61. Gilliam, A.D.; Watson, S.A. G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert. Opin. Biol. Ther., 2007, 7, 397-404.
62. Watson, S.A.; Grabowska, A.M.; El Zaatari, M.; Takhar, A. Gastrin - active participant or bystander in gastric carcinogenesis? Nat. Rev. Cancer, 2006, 6, 936-946
63. Wang, T.C.; Dangler, C.A.; Chen, D.; Goldenring, J.R.; Koh, T.; Raychowdhury, R.; Coffey, R.J.; Ito, S.; Varro, A.; Dockray, G.J.; Fox, J.G. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastro-enterology, 2000, 118, 36-47.
64. Burkitt, M.D.; Varro, A.; Pritchard, D.M. Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J. Gastroenterol., 2009, 15, 1-16.
65. Noble, P.J.; Wilde, G.; White, M.R.; Pennington, S.R.; Dockray, G.J.; Varro, A. Stimulation of gastrin-CCKB receptor promotes migration of gastric AGS cells via multiple paracrine pathways. Am. J. Physiol. Gastrointest. Liver Physiol., 2003, 284, G75-G84.
66. Wroblewski, L.E.; Pritchard, D.M.; Carter, S.; Varro, A. Gastrin-stimulated gastric epithelial cell invasion: the role and mechanism of increased matrix metalloproteinase 9 expression. Biochem. J., 2002, 365, 873-879
67. Todisco, A.; Ramamoorthy, S.; Witham, T.; Pausawasdi, N.; Srinivasan, S.; Dickinson, C.J.; Askari, F.K.; Krametter, D. Molecular mechanisms for the antiapoptotic action of gastrin. Am. J. Physiol. Gastrointest. Liver Physiol., 2001, 280, G298-G307.
68. Konturek, P.C.; Kania, J.; Kukharsky, V.; Ocker, S.; Hahn, E.G.; Konturek, S.J. Influence of gastrin on the expression of cyclooxygenase- 2, hepatocyte growth factor and apoptosis-related proteins in gastric epithelial cells. J. Physiol. Pharmacol., 2003, 54, 17-32.
69. Cui, G.; Takaishi, S.; Ai, W.; Betz, K.S.; Florholmen, J.; Koh, T.J.; Houghton, J.; Pritchard, D.M.; Wang, T.C. Gastrin-induced apoptosis contributes to carcinogenesis in the stomach. Lab. Invest., 2006, 86, 1037-1051
70. Przemeck, S.M.; Varro, A.; Berry, D.; Steele, I.; Wang, T.C.; Dockray, G.J.; Pritchard, D.M. Hypergastrinemia increases gastric epithelial susceptibility to apoptosis. Regul. Pept., 2008, 146, 147-156
71. Lefranc, F.; Mijatovic, T.; Mathieu, V.; Rorive, S.; Decaestecker, C.; Debeir, O.; Brotchi, J.; Van Ham, P.; Salmon, I.; Kiss, R. Characterization of gastrin-induced proangiogenic effects in vivo in orthotopic U373 experimental human glioblastomas and in vitro in human umbilical vein endothelial cells. Clin. Cancer Res., 2004, 10, 8250-8265
72. Clarke, P.A.; Dickson, J.H.; Harris, J.C.; Grabowska, A.; Watson, S.A. Gastrin enhances the angiogenic potential of endothelial cells via modulation of heparin-binding epidermal-like growth factor. Cancer Res., 2006, 66, 3504-3512
73. Okahata, H.; Nishi, Y.; Muraki, K.; Sumii, K.; Miyachi, Y.; Usui, T. Gastrin/cholecystokinin-like immunoreactivity in human blood cells. Life Sci., 1985, 36, 369-373
74. Iwata, N.; Murayama, T.; Matsumori, Y.; Ito, M.; Nagata, A.; Taniguchi, T.; Chihara, K.; Matsuo, Y.; Minowada, J.; Matsui, T. Autocrine loop through cholecystokinin-B/gastrin receptors involved in growth of human leukemia cells. Blood, 1996, 88, 2683-2689
75. Schmitz, F.; Schrader, H.; Otte, J.M.; Schmitz, H.; Stuber, E.; Herzig, K.H.; Schmidt, W.E. Identification of CCK-B/gastrin receptor splice variants in human peripheral blood mononuclear cells. Regul. Pept., 2001, 101, 25-33.
76. Sacerdote, P.; Wiedermann, C.J.; Wahl, L.M.; Pert, C.B.; Ruff, M.R. Visualization of cholecystokinin receptors on a subset of human monocytes and in rat spleen. Peptides, 1991, 12, 167-176
77. Lignon, M.F.; Bernad, N.; Martinez, J. Pharmacological characterization of type B cholecystokinin binding sites on the human JURKAT T lymphocyte cell line. Mol. Pharmacol., 1991, 39, 615-620
78. Lignon, M.F.; Bernad, N.; Martinez, J. Cholecystokinin increases intracellular Ca2+ concentration in the Human JURKAT T Lymphocyte cell line. Eur. J. Pharmacol., 1993, 245, 241-246
79. Mezey, E.; Palkovits, M. Localization of targets for antiulcer drugs in cells of the immune-system. Science, 1992, 258, 1662-1665
80. Cong, B.; Li, S.J.H.; Ling, Y.L.; Yao, Y.X.; Gu, Z.Y.; Wang, J.X.; You, H.Y. Expression and cell-specific localization of cholecystokinin receptors in rat lung. World J. Gastroenterol., 2003, 9, 1273-1277
81. Alvarez, A.; Ibiza, S.; Hernandez, C.; Alvarez-Barrientos, A.; Esplugues, J.V.; Calatayud, S. Gastrin induces leukocyte-endothelial cell interactions in vivo and contributes to the inflammation caused by Helicobacter pylori. FASEB J., 2006, 20, 2396-2398
82. Schmitz, F.; Otte, J.M.; Stechele, H.U.; Reimann, B.; Banasiewicz, T.; Folsch, U.R.; Schmidt, W.E.; Herzig, K.H. CCK-B/gastrin receptors in human colorectal cancer. Eur. J. Clin. Invest., 2001, 31, 812-820
83. Nichols, D.H.; Lovas, S.; Adrian, T.E.; Miller, C.A.; Murphy, R.F. Peptides bind to eosinophils in the rat stomach. Anat. Rec., 1998, 250, 172-181
84. Praissman, M.; Fox, R.L.; Walden, M.; Praissman, L.A.; Kromholz, N.W.; Zahra, T.; Abrar, N.; Feffer, S.E.; Grant, M. A novel gastrin-binding protein in the human eosinophil. Biochem. Biophys. Res. Commun., 1998, 243, 779-784
85. Sacerdote, P.; Ruff, M.R.; Pert, C.B. Cholecystokinin and the immune system: receptor-mediated chemotaxis of human and rat monocytes. Peptides, 1988, 9, 29-34.
86. DelaFuente, M.; Drummond, J.; DelRio, M.; Carrasco, M.; Hernanz, A. Modulation of murine peritoneal macrophage functions by gastrin. Peptides, 1996, 17, 219-224
87. DelaFuente, M.; Carrasco, M.; Hernanz, A. Modulation of human neutrophil function in vitro by gastrin. J. Endocrinol., 1997, 153, 475-483
88. Carrasco, M.; Hernanz, A.; DelaFuente, M. Effect of cholecystokinin and gastrin on human peripheral blood lymphocyte functions, implication of cyclic AMP and interleukin 2. Regul. Pept., 1997, 70, 135-142
89. Dornand, J.; Roche, S.; Michel, F.; Bali, J.P.; Cabane, S.; Favero, J.; Magous, R. Gastrin-CCK-B type receptors on human T lymphoblastoid Jurkat cells. Am. J. Physiol., 1995, 268, G522-G529.
90. Oiry, C.; Gagne, D.; Cottin, E.; Bernad, N.; Galleyrand, J.C.; Berge, G.; Lignon, M.F.; Eldin, P.; Le Cunff, M.; Leger, J.; Clerc, P.; Fourmy, D.; Martinez, J. CholecystokininB receptor from human Jurkat lymphoblastic T cells is involved in activator protein-1- responsive gene activation. Mol. Pharmacol., 1997, 52, 292-299
91. Ibiza, S.; Álvarez, A.; Romero, W.; Barrachina, M.D.; Esplugues, J.V.; Calatayud, S. Gastrin induces the interaction between human mononuclear leukocytes and endothelial cells through the endothelial expression of P-selectin and VCAM-1. Am. J. Physiol. Cell Physiol., 2009, Epub ahead of print.
92. Hiraoka, S.; Miyazaki, Y.; Kitamura, S.; Toyota, M.; Kiyohara, T.; Shinomura, Y.; Mukaida, N.; Matsuzawa, Y. Gastrin induces CXC chemokine expression in gastric epithelial cells through activation of NF-kappa B. Am. J. Physiol. Gastrointest. Liver Physiol., 2001, 281, G735-G742.
93. Subramaniam, D.; Ramalingam, S.; May, R.; Dieckgraefe, B.K.; Berg, D.E.; Pothoulakis, C.; Houchen, C.W.; Wang, T.C.; Anant, S. Gastrin-mediated interleukin-8 and cyclooxygenase-2 gene expression: differential transcriptional and posttranscriptional mechanisms. Gastroenterology, 2008, 134, 1070-1082
94. Zavros, Y.; Rathinavelu, S.; Kao, J.Y.; Todisco, A.; Del Valle, J.; Weinstock, J.V.; Low, M.J.; Merchant, J.L. Treatment of Helicobacter gastritis with IL-4 requires somatostatin. Proc. Natl. Acad. Sci. USA, 2003, 100, 12944-12949
95. Takaishi, S.; Cui, G.L.; Frederick, D.M.; Carlson, J.E.; Houghton, J.; Varro, A.; Dockray, G.J.; Ge, Z.M.; Whary, M.T.; Rogers, A.B.; Fox, J.G.; Wang, T.C. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer. Gastroenterology, 2005, 128, 1965-1983
96. Tharp, M.D.; Thirlby, R.; Sullivan, T.J. Gastrin induces histamine release from human cutaneous mast cells. J. Allergy Clin. Immunol., 1984, 74, 159-165
97. Juanola, C.; Giralt, M.; Jimenez, M.; Mourelle, M.; Vergara, P. Mucosal mast cells are involved in CCK disruption of MMC in the rat intestine. Am. J. Physiol. Gastrointest. Liver Physiol., 1998, 38, G63-G67.
98. Alvarez, A.; Ibiza, M.S.; Andrade, M.M.; Blas-Garcia, A.; Calatayud, S. Gastric antisecretory drugs induce leukocyte-endothelial cell interactions through gastrin release and activation of CCK-2 receptors. J. Pharmacol. Exp. Ther., 2007, 323, 406-413
99. Norsett, K.G.; Laegreid, A.; Langaas, M.; Worlund, S.; Fossmark, R.; Waldum, H.L.; Sandvik, A.K. Molecular characterization of rat gastric mucosal response to potent acid inhibition. Physiol. Genomics, 2005, 22, 24-32.
100. Zavros, Y.; Rieder, G.; Ferguson, A.; Samuelson, L.C.; Merchant, J.L. Hypergastrinemia in response to gastric inflammation suppresses somatostatin. Am. J. Physiol. Gastrointest. Liver Physiol., 2002, 282, G175-G183.
101. Friis-Hansen, L.; Rieneck, K.; Nilsson, H.O.; Wadstrom, T.; Rehfeld, J.F. Gastric inflammation, metaplasia, and tumor development in gastrin-deficient mice. Gastroenterology, 2006, 131, 246-258
102. Jain, R.N.; Samuelson, L.C. Transcriptional profiling of gastrin-regulated genes in mouse stomach. Physiol. Genomics, 2007, 29, 1-12.
103. Pazgier, M.; Hoover, D.M.; Yang, D.; Lu, W.; Lubkowski, J. Human beta-defensins. Cell. Mol. Life Sci., 2006, 63, 1294-1313
104. Kaetzel, C.S. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol. Rev., 2005, 206, 83-99.
105. Blumberg, H.; Dinh, H.; Trueblood, E.S.; Pretorius, J.; Kugler, D.; Weng, N.; Kanaly, S.T.; Towne, J.E.; Willis, C.R.; Kuechle, M.K.; Sims, J.E.; Peschon, J.J. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J. Exp. Med., 2007, 204, 2603-2614
106. Murphy, M.G.; Sytnik, B.; Kovacs, T.O.; Mertz, H.; Ewanik, D.; Shingo, S.; Lin, J.H.; Gertz, B.J.; Walsh, J.H. The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans. Clin. Pharmacol. Ther., 1993, 54, 533-539
107. Boyce, M.; Warrington, S.; Nentwich, H.; Norris, V.; Hull, R.; Black, J.W. Effect of repeated doses of YF476, a gastrin antagonist, on pentagastrin-induced changes in volume, H+ content and pH of gastric aspirate in healthy subjects. Br. J. Clin. Pharmacol., 2004, 57, 684.
108. Boyce, M.; Warrington, S.; Johnston, A.; Harris, A.; . Effect on gastric pH of repeated doses of YF476, a new gastrin antagonist, compared with omeprazole and placebo. Br. J. Clin. Pharmacol., 2000, 50, 383-384
109. Galeone, M.; Moise, G.; Ferrante, F.; Cacioli, D.; Casula, P.L.; Bignamini, A.A. Double-blind clinical comparison between a gastrin- receptor antagonist, proglumide, and a histamine H2-blocker, cimetidine. Curr. Med. Res. Opin., 1978, 5, 376-382
110. Lamers, C.B.; Jansen, J.B. The effect of a gastrin-receptor antagonist on gastric acid secretion and serum gastrin in the Zollinger- Ellison syndrome. J. Clin. Gastroenterol., 1983, 5, 21-24
111. Beltinger, J.; Hildebrand, P.; Drewe, J.; Christ, A.; Hlobil, K.; Ritz, M.; D'Amato, M.; Rovati, L.; Beglinger, C. Effects of spiroglumide, a gastrin receptor antagonist, on acid secretion in humans. Eur. J. Clin. Invest., 1999, 29, 153-159
112. Kramer, M.S.; Cutler, N.R.; Ballenger, J.C.; Patterson, W.M.; Mendels, J.; Chenault, A.; Shrivastava, R.; Matzura-Wolfe, D.; Lines, C.; Reines, S. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol. Psychiatry, 1995, 37, 462-466
113. Adams, J.B.; Pyke, R.E.; Costa, J.; Cutler, N.R.; Schweizer, E.; Wilcox, C.S.; Wisselink, P.G.; Greiner, M.; Pierce, M.W.; Pande, A.C. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J. Clin. Psychopharmacol., 1995, 15, 428-434
114. van Megen, H.J.; Westenberg, H.G.; den Boer, J.A.; Slaap, B.; Es- Radhakishun, F.; Pande, A.C. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology (Berl), 1997, 129, 243-248
115. Goddard, A.W.; Woods, S.W.; Money, R.; Pande, A.C.; Charney, D.S.; Goodman, W.K.; Heninger, G.R.; Price, L.H. Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Res., 1999, 85, 225-240
116. Pande, A.C.; Greiner, M.; Adams, J.B.; Lydiard, R.B.; Pierce, M.W. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Biol. Psychiatry, 1999, 46, 860-862
117. Kawasaki, D.; Emori, Y.; Eta, R.; Iino, Y.; Hamano, H.; Yoshinaga, K.; Tanaka, T.; Takei, M.; Watson, S.A. Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro. Cancer Chemother. Pharmacol., 2008, 61, 883-892